Imunon, Inc. (IMNN) - Net Profit

IMNN (Imunon) - company brandmark

Imunon, Inc. (IMNN) is scaling its DNA platform for ovarian cancer therapy, overcoming pressure from mRNA industry behemoths. The company's profit metric reflects current yield dynamics, where the value of the indicator is -0.01. The issuer's financial stability is based on strict cost limits and the protection of intellectual property, creating a foundation for future positive cash flow.

IMNN - imunon.com Company Net Income over the range 04/28/2023 - 10/30/2026

Comprehensive metric breakdowns and analytics for imunon.com (IMNN)

- price and consensus price forecast:
Stock Quotes Imunon|IMNN - Consensus Target
- market capitalization indicators:
Market Capitalization IMNN|IMNN - Total Company Value
- book capitalization data:
Equity per Share Imunon|IMNN - Company Book Value|Market-to-Book Ratio imunon.com|IMNN - Aggregate Company Assets
- debt and liquidity details:
Debt to Equity Ratio Imunon, Inc.|IMNN - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital Imunon|IMNN - Company Aggregate Debts|Debts to Net Assets IMNN|IMNN - Company Long-Term Debt|Company Short-Term Indebtedness Imunon|Quick Liquidity Indicator imunon.com
- earnings and market ratios statistics:
IMNN - Net Income
Fundamental valuation:IMNN - Celsion Corporation
Brand item of Imunon Inc

The investment attractiveness of Imunon, Inc. (IMNN) is based on the commercialization of DNA vaccines through partnerships with cancer research centers. The company's net profit dynamics reflect the efficiency of this synergy, measuring the deviation of current operating results from the long-term root-mean-square norm. Analyzing the trajectory of this net profit allows for an assessment of the business's fundamental stability and the risk of a drawdown should the trend reverse.

Main competitors

Net Income Tempus AI|Net Income QGEN|Net Profit ionispharma.com|Company Net Income Repligen (RGEN)|Avidity Biosciences Inc - Company Profit|Company Net Income CRISPR Therapeutics Corp CRSP|GeneDx Corp (WGS) - Company Net Income|RARE - Company Net Income|BEAM (beamtx.com) - Company Profit|SRPT (Sarepta) - Net Income|Twist Bioscience Inc - Final Profit|TXG (10x Genomics Corp) - Net Profit|Intellia Corp (NTLA) - Net Financial Result|Company Net Income Stoke Therapeutics (STOK)|biolifesolutions.com - Company Profit|Net Profit WVE (Wave Life Sciences Ltd.)|MAZE - Net Income|SION: Net Income|Net Financial Result Prime Medicine Bio PRME|TSHA: Net Profit|QURE - Net Financial Result|Company Net Income MeiraGTx|Net Income REGENXBIO Inc (RGNX)|Company Net Income Solid Bio (SLDB)|Ocugen Pharma - Company Profit|Company Net Income Pacific Biosciences PACB|BNTC: Company Profit|Design Therapeutics, Inc. - Net Profit|RCKT (Rocket Pharma) - Company Profit|4D Molecular Therapeutics Inc (FDMT) - Company Net Income|Company Profit LXEO|KRRO (Korro Bio Inc.) - Net Profit|Net Profit editasmedicine.com|Net Profit SLN|Net Financial Result proqr.com|Company Net Income Codexis CDXS|SGMO - Net Income|NAUT: Net Income|MGX - Net Profit|Precision BioSciences (DTIL) - Company Net Income|Company Profit GBIO|Company Net Income Boundless Bio, Inc|Company Net Income Exicure Corp XCUR|Company Net Income Phio Pharmaceuticals (PHIO)|mustangbio.com - Company Profit|TransCode Therapeutics, Inc. - Net Income|Final Profit BNGO|Applied DNA - Net Profit|Net Financial Result bluebird bio, Inc BLUE|immunoprecise.com (IPA) - Company Net Income|Company Profit OMGA|OMIC (Singular Genomics) - Net Profit|Net Income Regulus Therapeutics, Inc. (RGLS)|Net Income SYRS (Syros)|Net Financial Result Telesis Bio, Inc|Net Profit TCON (TRACON Pharmaceuticals)|Net Financial Result unitybiotechnology.com (UBX)